<DOC>
	<DOC>NCT02257151</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, pharmacokinetics, and target engagement of BMS-986142 in healthy subjects.</brief_summary>
	<brief_title>Study to Evaluate the Safety, Pharmacokinetics and Target Engagement of BMS-986142 in Healthy Subjects</brief_title>
	<detailed_description>Allocation: Randomized Controlled Trial (SAD/MAD) Masking: Double-Blind (SAD/MAD)</detailed_description>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com 1. Healthy male and female subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations 2. Body Mass Index (BMI) of 18 to 32 kg/m2, inclusive. BMI=weight (kg)/[height(m)]2 1. Any significant acute or chronic medical illness 2. Current or recent (within 3 months of study drug administration) gastrointestinal disease 3. Any major surgery within 4 weeks of study drug administration 4. Any gastrointestinal surgery that could impact upon the absorption of study drug 5. Donation of blood to a blood bank or in a clinical study (except a screening visit) within 4 weeks of study drug administration (within 2 weeks for plasma only)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Volunteers</keyword>
</DOC>